Amarin Corp Plc (AMRN)

[Laurent Maldague]

So Nissen was teasing and hyping the CLEAR trial just for this? A 13% RRR in statin intolerant patients.

The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P=0.004)

The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels.

Don't get me wrong, i'm happy there's another option out there for statin intolerant people. Just felt like they were trying create hype/fanfare for the results. IPE clearly has no equal.

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2215024
https://www.tctmd.com/news/clear-cvd-benefit-bempedoic-acid-clear-outcomes